5332592025-04-012025-06-305332592025-06-305332592025-04-012025-06-30in-capmkt:OtherExpenses1Member5332592025-04-012025-06-30in-capmkt:ReportableSegments1Member5332592025-04-012025-06-30in-capmkt:ReportableSegments2Member5332592025-04-012025-06-30in-capmkt:ReportableSegments1Member5332592025-04-012025-06-30in-capmkt:ReportableSegments2Member5332592025-04-012025-06-30in-capmkt:ReportableSegments1Member5332592025-06-30in-capmkt:ReportableSegments1Member5332592025-04-012025-06-30in-capmkt:ReportableSegments2Member5332592025-06-30in-capmkt:ReportableSegments2Member5332592025-04-012025-06-30in-capmkt:ReportableSegments1Member5332592025-06-30in-capmkt:ReportableSegments1Member5332592025-04-012025-06-30in-capmkt:ReportableSegments2Member5332592025-06-30in-capmkt:ReportableSegments2Member5332592025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares533259SASTASUNDRNOTLISTEDINE019J01013SASTASUNDAR VENTURES LIMITEDMain BoardEquity2025-04-012026-03-312025-08-122025-08-04INRLakhsQuarterlyFirst quarterMulti segment2025-08-1215:30:002025-08-1216:30:00Not applicable2025-04-012025-06-30UnauditedConsolidated20160000001968750000277834200070490002984282000253818000323810000025190002602154000-287120001734090008600001168300000001743210002936234000301866000030186600031150003283000035945000265921000000026592100024300002683510002391170002680400024083600027515000318105000107.527.52007.527.520001. The above Unaudited Consolidated Financial Results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 12, 2025. The Limited Review for the quarter ended June 30, 2025 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulation, 2015. <BR> <BR> 2.The Group has identified the following segments : <BR> <BR> a. Financial Services - consists mainly of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. <BR> <BR> b. Healthcare Network - includes activities for pathology, food processing and marketing of healthcare and OTC products through e-commerce portal and diagnostic services which consist of pathological / radiological investigations. <BR> <BR> 3. Exceptional items represent the gain on following transaction/ event: <BR> <BR> a. During the Financial Year 2022-23, subsidiaries of the Company had expensed Rs. 796.45 Lakhs under the heading “Exceptional Item”. During the previous year, Sastasundar Healthbuddy Limited, subsidiary of the Company has now recovered Rs. 128.00 Lakhs against the aforesaid amount which has been booked as income in the consolidated financial result for the year ended March 31, 2025 under the heading “exceptional item” including Rs. 28.00 Lakhs of previous quarter March 2025. <BR> <BR> b. During the previous year, the subsidiary of the company, Sastasundar Healthbuddy Limited, has liquidated its investment held in the form of 0.01% Non-Cumulative Compulsory Convertible Preference share and Equity shares in Flipkart Health Limited on 29th October 2024 as per Share Purchase Agreement dated 28th October 2024 and received a consideration of Rs. 9,717.29 Lakhs in aggregate. <BR> This has resultant loss of Rs. 19,118.54 Lakhs has been booked as exceptional items in the consolidated financial result for the year ended March 31, 2025. <BR> <BR> c. During the previous year, the management of one of the step down subsidiary, Genu Path Labs Limited, has evaluated its business operation and the management is of the opinion that the Property, Plant & Equipment as held by it needs to be impaired. Accordingly the company has accounted for an impairment loss of Rs 72.37 Lakhs and disclosed the same as Exceptional item in the consolidated financial result for the year ended March 31, 2025. <BR> <BR> 4. a. During the year ended 31st March 2025, the subsidiary of the Company, Sastasundar Healthbuddy Limited, has entered into an agreement to dispose of its subsidiary, Happy Mate Foods Limited, and accordingly classified the investment in the said entity as Asset Held for Sale in accordance with Ind AS 105 – Non-current Assets Held for Sale and Discontinued Operations. <BR> <BR> On May 30, 2025, the sale of Happy Mate Foods Limited was completed, and the entity ceased to be a subsidiary of Sastasundar Healthbuddy Limited with effect from that date. <BR> <BR> 5. During the previous year, the subsidiary of the company, Sastasundar Healthbuddy Limited, has liquidated its investment in Associate Company i.e. Flipkart Health Limited on October 29, 2024. Share of Profit/ (Loss) from an associate company has been consolidated till October 29, 2024. <BR> <BR> 6. Genu Path Labs Limited, step- down subsidiary of the company, commenced its operations in the diagnostics and healthcare services segment in 2018 with a vision to establish itself as a trusted brand. Since inception, the company has undertaken several initiatives to develop its service network and physical presence. However, these efforts have not yielded the expected outcomes, resulting in operational losses. Additionally, Sastasundar Healthbuddy Limited, parent company of the Genu Path Labs Limited has assured its continued financial support to implement the revised strategies aimed at reviving and strengthening the business. <BR> <BR> 7. The figure for the quarter ended March 31, 2025 are the balancing figure between audited figure in respect of the full financial year and the unaudited published period to date reviewed figures upto the end of the third quarter December 31, 2024 which were subjected to a limited review. <BR> <BR> 8. Previous Period/ Year figures have been re-grouped / re-classified wherever necessary.Other Expenses174321000Financial Services198892000Healthcare Network2785390000298428200002984282000Financial Services194959000Healthcare Network-13087700064082000860000-238644000301866000Financial Services1217959000Healthcare Network812240000093403590004800800009820439000Financial Services75565000Healthcare Network818439000894004000127350009067390002. The Group has identified the following segments : <BR> a. Financial Services - consists mainly of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. <BR> b. Healthcare Network - includes activities for pathology, food processing and marketing of healthcare and OTC products through e-commerce portal and diagnostic services which consist of pathological / radiological investigations. <BR> Items that will be not reclassified subsequently to profit or loss24120002412000-1800002430000